EU · EudraLex Vol.4
EU GMP Part I, Chapter 5
Production
Status of the document: Revisiona.
Table of contents
- PrinciplePrinciple
- 5.1Production should be performed and supervised by competent people.
- 5.2All handling of materials and products, such as receipt and quarantine, sampling, storage, labelling, dispensing, processing, packaging and…
- 5.3All incoming materials should be checked to ensure that the consignment corresponds to the order. Containers should be cleaned where necess…
- 5.4Damage to containers and any other problem which might adversely affect the quality of a material should be investigated, recorded and repo…
- 5.5Incoming materials and finished products should be physically or administratively quarantined immediately after receipt or processing, unti…
- 5.6Intermediate and bulk products purchased as such should be handled on receipt as though they were starting materials.
- 5.7All materials and products should be stored under the appropriate conditions established by the manufacturer and in an orderly fashion to p…
- 5.8Checks on yields, and reconciliation of quantities, should be carried out as necessary to ensure that there are no discrepancies outside ac…
- 5.9Operations on different products should not be carried out simultaneously or consecutively in the same room unless there is no risk of mix-…
- 5.10At every stage of processing, products and materials should be protected from microbial and other contamination.
- 5.11When working with dry materials and products, special precautions should be taken to prevent the generation and dissemination of dust. This…
- 5.12At all times during processing, all materials, bulk containers, major items of equipment and where appropriate rooms used should be labelle…
- 5.13Labels applied to containers, equipment or premises should be clear, unambiguous and in the company’s agreed format. It is often helpful in…
- 5.14Checks should be carried out to ensure that pipelines and other pieces of equipment used for the transportation of products from one area t…
- 5.15Any deviation from instructions or procedures should be avoided as far as possible. If a deviation occurs, it should be approved in writing…
- 5.16Access to production premises should be restricted to authorised personnel.
- 5.17Normally, the production of non-medicinal products should be avoided in areas and with equipment destined for the production of medicinal p…
- 5.18Contamination of a starting material or of a product by another material or product should be prevented. This risk of accidental cross-cont…
- 5.19Cross-contamination should be prevented by attention to design of the premises and equipment as described in Chapter 3. This should be supp…
- 5.20A Quality Risk Management process, which includes a potency and toxicological evaluation, should be used to assess and control the cross-co…
- 5.21The outcome of the Quality Risk Management process should be the basis for determining the extent of technical and organisational measures…
- 5.22Measures to prevent cross-contamination and their effectiveness should be reviewed periodically according to set procedures.
- 5.23Validation studies should reinforce Good Manufacturing Practice and be conducted in accordance with defined procedures. Results and conclus…
- 5.24When any new manufacturing formula or method of preparation is adopted, steps should be taken to demonstrate its suitability for routine pr…
- 5.25Significant amendments to the manufacturing process, including any change in equipment or materials, which may affect product quality and/o…
- 5.26Processes and procedures should undergo periodic critical re-validation to ensure that they remain capable of achieving the intended result…
- 5.27The selection, qualification, approval and maintenance of suppliers of starting materials, together with their purchase and acceptance, sho…
- 5.28The quality requirements established by the manufacturer for the starting materials should be discussed and agreed with the suppliers. Appr…
- 5.29For the approval and maintenance of suppliers of active substances and excipients, the following is required: Active substances[1] Supply c…
- 5.30For each delivery of starting material the containers should be checked for integrity of package, including tamper evident seal where relev…
- 5.31If one material delivery is made up of different batches, each batch must be considered as separate for sampling, testing and release.
- 5.32Starting materials in the storage area should be appropriately labelled (see section 13). Labels should bear at least the following informa…
- 5.33There should be appropriate procedures or measures to assure the identity of the contents of each container of starting material. Bulk cont…
- 5.34Only starting materials which have been released by the Quality Control department and which are within their retest period should be used.
- 5.35Manufacturers of finished products are responsible for any testing of starting materials2 as described in the marketing authorisation dossi…
- 5.36The rationale for the outsourcing of this testing should be justified and documented and the following requirements should be fulfilled: i.…
- 5.37Starting materials should only be dispensed by designated persons, following a written procedure, to ensure that the correct materials are…
- 5.38Each dispensed material and its weight or volume should be independently checked and the check recorded.
- 5.39Materials dispensed for each batch should be kept together and conspicuously labelled as such.
- 5.40Before any processing operation is started, steps should be taken to ensure that the work area and equipment are clean and free from any st…
- 5.41Intermediate and bulk products should be kept under appropriate conditions.
- 5.42Critical processes should be validated (see "Validation" in this Chapter).
- 5.43Any necessary in-process controls and environmental controls should be carried out and recorded.
- 5.44Any significant deviation from the expected yield should be recorded and investigated.
- 5.45The selection, qualification, approval and maintenance of suppliers of primary and printed packaging materials shall be accorded attention…
- 5.46Particular attention should be paid to printed materials. They should be stored in adequately secure conditions such as to exclude unauthor…
- 5.47Each delivery or batch of printed or primary packaging material should be given a specific reference number or identification mark.
- 5.48Outdated or obsolete primary packaging material or printed packaging material should be destroyed and this disposal recorded.
- 5.49When setting up a programme for the packaging operations, particular attention should be given to minimising the risk of cross-contaminatio…
- 5.50Before packaging operations are begun, steps should be taken to ensure that the work area, packaging lines, printing machines and other equ…
- 5.51The name and batch number of the product being handled should be displayed at each packaging station or line.
- 5.52All products and packaging materials to be used should be checked on delivery to the packaging department for quantity, identity and confor…
- 5.53Containers for filling should be clean before filling. Attention should be given to avoid and remove any contaminants such as glass fragmen…
- 5.54Normally, filling and sealing should be followed as quickly as possible by labelling. If it is not the case, appropriate procedures should…
- 5.55The correct performance of any printing operation (for example code numbers, expiry dates) to be done separately or in the course of the pa…
- 5.56Special care should be taken when using cut-labels and when over-printing is carried out off-line. Roll-feed labels are normally preferable…
- 5.57Checks should be made to ensure that any electronic code readers, label counters or similar devices are operating correctly.
- 5.58Printed and embossed information on packaging materials should be distinct and resistant to fading or erasing.
- 5.59On-line control of the product during packaging should include at least checking the following: i. General appearance of the packages; ii.…
- 5.60Products which have been involved in an unusual event should only be reintroduced into the process after special inspection, investigation…
- 5.61Any significant or unusual discrepancy observed during reconciliation of the amount of bulk product and printed packaging materials and the…
- 5.62Upon completion of a packaging operation, any unused batch-coded packaging materials should be destroyed and the destruction recorded. A do…
- 5.63Finished products should be held in quarantine until their final release under conditions established by the manufacturer.
- 5.64The evaluation of finished products and documentation which is necessary before release of product for sale is described in Chapter 6 (Qual…
- 5.65After release, finished products should be stored as usable stock under conditions established by the manufacturer.
- 5.66Rejected materials and products should be clearly marked as such and stored separately in restricted areas. They should either be returned…
- 5.67The reprocessing of rejected products should be exceptional. It is only permitted if the quality of the final product is not affected, if t…
- 5.68The recovery of all or part of earlier batches which conform to the required quality by incorporation into a batch of the same product at a…
- 5.69The need for additional testing of any finished product which has been reprocessed, or into which a recovered product has been incorporated…
- 5.70Products returned from the market and which have left the control of the manufacturer should be destroyed unless without doubt their qualit…
- 5.71The manufacturer should report to the marketing authorisation holder (MAH) any constraints in manufacturing operations which may result in…
Cover page and contents (original)
Ref. Ares(2015)283689 - 23/01/2015
CHAPTER 5 PRODUCTION EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL
Health systems and products Medicinal products – quality, safety and efficacy
Brussels, 13 August 2014
EudraLex
The Rules Governing Medicinal Products in the European Union
Volume 4 EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use
Part 1 Chapter 5: Production
Legal basis for publishing the detailed guidelines: Article 47 of Directive 2001/83/EC on the Community code relating to medicinal products for human use and Article 51 of Directive 2001/82/EC on the Community code relating to veterinary medicinal products. This document provides guidance for the interpretation of the principles and guidelines of good manufacturing practice (GMP) for medicinal products as laid down in Directive 2003/94/EC for medicinal products for human use and Directive 91/412/EEC for veterinary use.
Status of the document: Revisiona.
Reasons for changes: Changes have been made to sections 17 to 21, including adding a new section, to improve the guidance on prevention of cross-contamination and to refer to toxicological assessment. Changes were also introduced in sections 27 to 30, including adding a new section, on the qualification of suppliers in order to reflect the legal obligation of manufacturing authorisation holders to ensure that active substances are produced in accordance with GMP. The changes include supply chain traceability. Sections 35 and 36 are inserted to clarify and harmonise expectations of manufacturers regarding the testing of starting materials while section 71 introduces guidance on notification of restrictions in supply.
Deadline for coming into operation: 1 March 2015. However, the toxicological evaluation mentioned in section 20 has to be carried out:
a In January 2015 the deadline for coming into operation was adapted with regard to the toxicological evaluation to align with the coming effect of the EMA guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities. Furthermore, correction of the reference in footnote 2 took place. Commission Européenne, B-1049 Bruxelles / Europese Commissie, B-1049 Brussel – Belgium. Telephone: (32-2) 299 11 11
• from 1 June 2015 onwards for any medicinal product newly introduced into shared manufacturing facilities;
• before 1 December 2015 for medicinal products already produced in a shared manufacturing facility producing only medicinal products for human use or producing both medicinal products for human use and veterinary medicinal products on 31 May 2015;
• before 1 June 2016 for veterinary medicinal products already produced in a shared manufacturing facility producing only veterinary medicinal products on 31 May 2015.
Source: European Commission, DG SANTE · © European Union. Reuse is authorised provided the source is acknowledged (Commission Decision 2011/833/EU on the reuse of Commission documents). · retrieved 2026-11-15